메뉴 건너뛰기




Volumn 122, Issue 7, 2015, Pages 1375-1394

Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets

Author keywords

[No Author keywords available]

Indexed keywords

ALG 1001; ANGIOPEPTIN; ANGIOPOIETIN 2 INHIBITOR; BETAMETHASONE; CHEMOKINE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLODEXTRIN; DANAZOL; DARAPLADIB; DEXAMETHASONE; ERYTHROPOIETIN; EXENDIN 4; ICO 007; INTERLEUKIN INHIBITOR; LOTEPREDNOL; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MECAMYLAMINE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE C INHIBITOR; PROTEINASE INHIBITOR; RTP 801; SQUALAMINE; SRC KINASE INHIBITOR; TEPROTUMUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR ADHESION PROTEIN 1 INHIBITOR; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

EID: 84937739093     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.03.024     Document Type: Review
Times cited : (428)

References (134)
  • 1
    • 84907573731 scopus 로고    scopus 로고
    • 6th ed. International Diabetes Federation Brussels, Belgium
    • IDF Diabetes Atlas 6th ed. 2013 International Diabetes Federation Brussels, Belgium
    • (2013) IDF Diabetes Atlas
  • 2
    • 84859030420 scopus 로고    scopus 로고
    • Meta-Analysis for Eye Disease (META-EYE) study group. Global prevalence and risk factors of diabetic retinopathy
    • J.W. Yau, S.L. Rogers, R. Kawasaki, and et al. Meta-Analysis for Eye Disease (META-EYE) study group. Global prevalence and risk factors of diabetic retinopathy Diabetes Care 35 2012 556 564
    • (2012) Diabetes Care , vol.35 , pp. 556-564
    • Yau, J.W.1    Rogers, S.L.2    Kawasaki, R.3
  • 3
    • 0028896755 scopus 로고
    • The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XV: the long-term incidence of macular edema
    • R. Klein, B.E.K. Klein, S.E. Moss, and K.J. Cruickshanks The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XV: the long-term incidence of macular edema Ophthalmology 102 1995 7 16
    • (1995) Ophthalmology , vol.102 , pp. 7-16
    • Klein, R.1    Klein, B.E.K.2    Moss, S.E.3    Cruickshanks, K.J.4
  • 4
    • 77951843664 scopus 로고    scopus 로고
    • Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents
    • N.H. White, W. Sun, P.A. Cleary DCCT-EDIC Research Group Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents Diabetes 59 2010 1244 1253
    • (2010) Diabetes , vol.59 , pp. 1244-1253
    • White, N.H.1    Sun, W.2    Cleary, P.A.3
  • 5
    • 0028896755 scopus 로고
    • The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of diabetic macular edema
    • R. Klein, B.E. Klein, S.E. Moss, and K.J. Cruickshanks The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of diabetic macular edema Ophthalmology 102 1995 7 16
    • (1995) Ophthalmology , vol.102 , pp. 7-16
    • Klein, R.1    Klein, B.E.2    Moss, S.E.3    Cruickshanks, K.J.4
  • 6
    • 0001900504 scopus 로고    scopus 로고
    • Etiologic mechanisms in diabetic retinopathy
    • Ryan SJ, ed., St. Louis, MO: Mosby
    • Frank RN. Etiologic mechanisms in diabetic retinopathy. In: Ryan SJ, ed. Retina. Vol 2. St. Louis, MO: Mosby; 2001:1259-94.
    • (2001) Retina , vol.2 , pp. 1259-1294
    • Frank, R.N.1
  • 7
    • 0003680197 scopus 로고
    • Photocoagulation for diabetic macular edema. ETDRS Report No. 1
    • Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. ETDRS Report No. 1 Arch Ophthalmol 10 1985 1796 1806
    • (1985) Arch Ophthalmol , vol.10 , pp. 1796-1806
  • 8
    • 0042932653 scopus 로고    scopus 로고
    • Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity of scales
    • C.P. Wilkinson, F.L. Ferris 3rd, R.E. Klein, and et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity of scales Ophthalmology 110 2003 1677 1682
    • (2003) Ophthalmology , vol.110 , pp. 1677-1682
    • Wilkinson, C.P.1    Ferris, F.L.2    Klein, R.E.3
  • 9
    • 48149104805 scopus 로고    scopus 로고
    • Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema
    • D.J. Browning, A.R. Glassman, L.P. Aiello, and et al. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema Ophthalmology 115 2008 1366 1371
    • (2008) Ophthalmology , vol.115 , pp. 1366-1371
    • Browning, D.J.1    Glassman, A.R.2    Aiello, L.P.3
  • 10
    • 33847130442 scopus 로고    scopus 로고
    • Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema
    • D.J. Browning, A.R. Glassman, L.P. Aiello, and et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema Ophthalmology 115 2007 525 536
    • (2007) Ophthalmology , vol.115 , pp. 525-536
    • Browning, D.J.1    Glassman, A.R.2    Aiello, L.P.3
  • 11
    • 84911976767 scopus 로고    scopus 로고
    • Prevalence and risk factors for diabetic macular edema in the United States
    • R. Varma, N.M. Bressler, Q.V. Doan, and et al. Prevalence and risk factors for diabetic macular edema in the United States JAMA Ophthalmol 132 2014 1334 1340
    • (2014) JAMA Ophthalmol , vol.132 , pp. 1334-1340
    • Varma, R.1    Bressler, N.M.2    Doan, Q.V.3
  • 12
    • 0021136256 scopus 로고
    • The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years
    • R. Klein, B.E. Klein, S.E. Moss, and et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years Arch Ophthalmol 102 1984 520 526
    • (1984) Arch Ophthalmol , vol.102 , pp. 520-526
    • Klein, R.1    Klein, B.E.2    Moss, S.E.3
  • 13
    • 0021191759 scopus 로고
    • The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years
    • R. Klein, B.E. Klein, S.E. Moss, and et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years Arch Ophthalmol 102 1984 527 532
    • (1984) Arch Ophthalmol , vol.102 , pp. 527-532
    • Klein, R.1    Klein, B.E.2    Moss, S.E.3
  • 14
    • 34547691507 scopus 로고    scopus 로고
    • Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study
    • H.A. Keenan, T. Costacou, J.K. Sun, and et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study Diabetes Care 30 2007 1995 1997
    • (2007) Diabetes Care , vol.30 , pp. 1995-1997
    • Keenan, H.A.1    Costacou, T.2    Sun, J.K.3
  • 15
    • 79956213781 scopus 로고    scopus 로고
    • Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-year medalist study
    • J.K. Sun, H.A. Keenan, J.D. Cavallerano, and et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-year medalist study Diabetes Care 34 2011 968 974
    • (2011) Diabetes Care , vol.34 , pp. 968-974
    • Sun, J.K.1    Keenan, H.A.2    Cavallerano, J.D.3
  • 16
    • 0027370108 scopus 로고
    • The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
    • The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
    • (1993) N Engl J Med , vol.329 , pp. 977-986
  • 17
    • 0032710096 scopus 로고    scopus 로고
    • The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for Type 2 diabetes
    • P. King, I. Peacock, and R. Donnelly The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for Type 2 diabetes Br J Clin Pharmacol 48 1999 643 648
    • (1999) Br J Clin Pharmacol , vol.48 , pp. 643-648
    • King, P.1    Peacock, I.2    Donnelly, R.3
  • 18
    • 0348048874 scopus 로고    scopus 로고
    • Diabetic retinopathy
    • R.N. Frank Diabetic retinopathy N Engl J Med 350 2004 48 58
    • (2004) N Engl J Med , vol.350 , pp. 48-58
    • Frank, R.N.1
  • 19
    • 58149252632 scopus 로고    scopus 로고
    • Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial
    • N.H. White, W. Sun, P.A. Cleary Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial Arch Ophthalmol 126 2008 1707 1715
    • (2008) Arch Ophthalmol , vol.126 , pp. 1707-1715
    • White, N.H.1    Sun, W.2    Cleary, P.A.3
  • 20
    • 84897489404 scopus 로고    scopus 로고
    • Evaluating the role of epigenetic histone modifications in the metabolic memory if type diabetes
    • F. Miao, Z. Chen, S. Genuth, and et al. Evaluating the role of epigenetic histone modifications in the metabolic memory if type diabetes Diabetes 63 2014 1748 1762
    • (2014) Diabetes , vol.63 , pp. 1748-1762
    • Miao, F.1    Chen, Z.2    Genuth, S.3
  • 21
    • 77954654472 scopus 로고    scopus 로고
    • Effects of medical therapies on retinopathy progression in type 2 diabetes
    • The ACCORD Study Group, and ACCORD Eye Study Group Effects of medical therapies on retinopathy progression in type 2 diabetes N Engl J Med 363 2010 233 244
    • (2010) N Engl J Med , vol.363 , pp. 233-244
  • 22
    • 69949166204 scopus 로고    scopus 로고
    • Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial
    • J.W. Beulens, A. Patel, J.R. Vingerling, and et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial Diabetologia 52 2009 2027 2036
    • (2009) Diabetologia , vol.52 , pp. 2027-2036
    • Beulens, J.W.1    Patel, A.2    Vingerling, J.R.3
  • 23
    • 84856369864 scopus 로고    scopus 로고
    • Differential association of serum lipids with diabetic retinopathy and diabetic macular edema
    • R. Benarous, M.B. Sasongko, S. Qureshi, and et al. Differential association of serum lipids with diabetic retinopathy and diabetic macular edema Invest Ophthalmol Vis Sci 52 2011 7464 7469
    • (2011) Invest Ophthalmol Vis Sci , vol.52 , pp. 7464-7469
    • Benarous, R.1    Sasongko, M.B.2    Qureshi, S.3
  • 24
    • 0029757496 scopus 로고    scopus 로고
    • Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22
    • E.Y. Chew, M.L. Klein, F.L. Ferris 3rd, and et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22 Arch Ophthalmol 114 1996 1079 1084
    • (1996) Arch Ophthalmol , vol.114 , pp. 1079-1084
    • Chew, E.Y.1    Klein, M.L.2    Ferris, F.L.3
  • 25
    • 36049001784 scopus 로고    scopus 로고
    • Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
    • A.C. Keech, P. Mitchell, P.A. Summanen, and et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial Lancet 370 2007 1687 1697
    • (2007) Lancet , vol.370 , pp. 1687-1697
    • Keech, A.C.1    Mitchell, P.2    Summanen, P.A.3
  • 26
    • 84872024160 scopus 로고    scopus 로고
    • Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy
    • S.F. Abcouwer Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy Diabetes 62 2013 36 38
    • (2013) Diabetes , vol.62 , pp. 36-38
    • Abcouwer, S.F.1
  • 27
    • 77952604460 scopus 로고    scopus 로고
    • Atorvastatin for diabetic macular edema in patients with diabetes mellitus and elevated serum cholesterol
    • T.D. Panagiotoglou, E.S. Ganotakis, G.D. Kymionis, and et al. Atorvastatin for diabetic macular edema in patients with diabetes mellitus and elevated serum cholesterol Ophthalmic Surg Lasers Imaging 41 2010 316 322
    • (2010) Ophthalmic Surg Lasers Imaging , vol.41 , pp. 316-322
    • Panagiotoglou, T.D.1    Ganotakis, E.S.2    Kymionis, G.D.3
  • 28
    • 84874409065 scopus 로고    scopus 로고
    • Atorvastatin in clinically-significant macular edema in diabetics with a normal lipid profile
    • S. Narang, S. Sood, B. Kaur, and et al. Atorvastatin in clinically-significant macular edema in diabetics with a normal lipid profile Nepal J Ophthalmol 4 2012 23 28
    • (2012) Nepal J Ophthalmol , vol.4 , pp. 23-28
    • Narang, S.1    Sood, S.2    Kaur, B.3
  • 29
    • 0030725948 scopus 로고    scopus 로고
    • Clustering of long-term complications in families with diabetes in the diabetes control and complications trial
    • The Diabetes Control and Complications Trial research Group Clustering of long-term complications in families with diabetes in the diabetes control and complications trial Diabetes 46 1997 1829 1839
    • (1997) Diabetes , vol.46 , pp. 1829-1839
  • 30
    • 44349193611 scopus 로고    scopus 로고
    • Promoter polymorphism in severe diabetic eye and kidney complications
    • Z. Tong, Z. Yang, S. Patel, and et al. Promoter polymorphism in severe diabetic eye and kidney complications Proc Natl Acad Sci U S A 105 2008 6998 7003
    • (2008) Proc Natl Acad Sci U S A , vol.105 , pp. 6998-7003
    • Tong, Z.1    Yang, Z.2    Patel, S.3
  • 31
    • 84892714171 scopus 로고    scopus 로고
    • Challenges in elucidating the genetics of diabetic retinopathy
    • J.Z. Kuo, T.Y. Wong, and J.I. Rotter Challenges in elucidating the genetics of diabetic retinopathy JAMA Ophthalmol 132 2014 96 107
    • (2014) JAMA Ophthalmol , vol.132 , pp. 96-107
    • Kuo, J.Z.1    Wong, T.Y.2    Rotter, J.I.3
  • 32
    • 0026738687 scopus 로고
    • Electrical method for detection of endothelial cell shape change in real time: assessment of endothelial barrier function
    • C. Tiruppathi, A.B. Malik, P.J. Del Vecchio, and et al. Electrical method for detection of endothelial cell shape change in real time: assessment of endothelial barrier function Proc Natl Acad Sci U S A 89 1992 7919 7923
    • (1992) Proc Natl Acad Sci U S A , vol.89 , pp. 7919-7923
    • Tiruppathi, C.1    Malik, A.B.2    Del Vecchio, P.J.3
  • 33
    • 84880080527 scopus 로고    scopus 로고
    • My D88 pathways in leukocytes affect the retina in diabetes
    • L. Tang, C.A. Lee, D. Yunpeng, and et al. My D88 pathways in leukocytes affect the retina in diabetes PLoS One 8 2013 e68871
    • (2013) PLoS One , vol.8
    • Tang, L.1    Lee, C.A.2    Yunpeng, D.3
  • 34
    • 22144457454 scopus 로고    scopus 로고
    • The Ins2Akita mouse as a model of early retinal complications in diabetes
    • A.J. Barber, D.A. Antonetti, T.S. Kern, and et al. The Ins2Akita mouse as a model of early retinal complications in diabetes Invest Ophthalmol Vis Sci 46 2005 2210 2218
    • (2005) Invest Ophthalmol Vis Sci , vol.46 , pp. 2210-2218
    • Barber, A.J.1    Antonetti, D.A.2    Kern, T.S.3
  • 36
    • 33846991924 scopus 로고    scopus 로고
    • Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation
    • B.B. Gao, A. Clermont, Rook, and et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation Nat Med 13 2007 181 188
    • (2007) Nat Med , vol.13 , pp. 181-188
    • Gao, B.B.1    Clermont, A.2    Rook3
  • 37
    • 84863490715 scopus 로고    scopus 로고
    • Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals
    • R. Robinson, V.A. Barathi, and S.S. Chaurasia Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals Dis Model Mech 5 2012 444 456
    • (2012) Dis Model Mech , vol.5 , pp. 444-456
    • Robinson, R.1    Barathi, V.A.2    Chaurasia, S.S.3
  • 38
    • 84855703359 scopus 로고    scopus 로고
    • Evidence for diffuse central retinal edema in vivo in diabetic male Sprague Dawley rats
    • B.A. Berkowitz, D. Bissig, Y. Ye, and et al. Evidence for diffuse central retinal edema in vivo in diabetic male Sprague Dawley rats PLoS One 7 2012 e29619
    • (2012) PLoS One , vol.7
    • Berkowitz, B.A.1    Bissig, D.2    Ye, Y.3
  • 39
    • 20044376702 scopus 로고    scopus 로고
    • The pathobiology of diabetic complications: a unifying mechanism
    • M. Brownlee The pathobiology of diabetic complications: a unifying mechanism Diabetes 54 2005 1615 1625
    • (2005) Diabetes , vol.54 , pp. 1615-1625
    • Brownlee, M.1
  • 40
    • 84937730548 scopus 로고    scopus 로고
    • Diabetic macular edema: molecular mechanisms
    • A. Das, T. Friberg, Wolters Kluwer Philadelphia, PA
    • S. Rangasamy, R. Srinivasan, P.G. McGuire, and A. Das Diabetic macular edema: molecular mechanisms A. Das, T. Friberg, Therapy for Ocular Angiogenesis 2011 Wolters Kluwer Philadelphia, PA 88 99
    • (2011) Therapy for Ocular Angiogenesis , pp. 88-99
    • Rangasamy, S.1    Srinivasan, R.2    McGuire, P.G.3    Das, A.4
  • 41
    • 0031737671 scopus 로고    scopus 로고
    • Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content
    • D.A. Antonetti, A.J. Barber, S. Khin, and et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content Diabetes 47 1998 1953 1959
    • (1998) Diabetes , vol.47 , pp. 1953-1959
    • Antonetti, D.A.1    Barber, A.J.2    Khin, S.3
  • 42
    • 34548397756 scopus 로고    scopus 로고
    • Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes
    • D. Navaratna, P.G. McGuire, G. Menicucci, and A. Das Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes Diabetes 56 2007 2380 2387
    • (2007) Diabetes , vol.56 , pp. 2380-2387
    • Navaratna, D.1    McGuire, P.G.2    Menicucci, G.3    Das, A.4
  • 43
    • 0033551811 scopus 로고    scopus 로고
    • Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occludens
    • D.A. Antonetti, A.J. Barber, L.A. Hollinger, and et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occludens J Biol Chem 274 1999 23463 23467
    • (1999) J Biol Chem , vol.274 , pp. 23463-23467
    • Antonetti, D.A.1    Barber, A.J.2    Hollinger, L.A.3
  • 44
    • 0029973474 scopus 로고    scopus 로고
    • Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy
    • M. Mizutani, T.S. Kern, and M. Lorenzi Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy J Clin Invest 15 1996 2883 2890
    • (1996) J Clin Invest , vol.15 , pp. 2883-2890
    • Mizutani, M.1    Kern, T.S.2    Lorenzi, M.3
  • 45
    • 0000099141 scopus 로고
    • Retinal vascular patterns. VI. Mural cells of the retinal capillaries
    • T. Kuwabara, and D.G. Cogan Retinal vascular patterns. VI. Mural cells of the retinal capillaries Arch Ophthalmol 69 1963 492 502
    • (1963) Arch Ophthalmol , vol.69 , pp. 492-502
    • Kuwabara, T.1    Cogan, D.G.2
  • 46
    • 0023884525 scopus 로고
    • ATP causes retinal pericytes to contract in vitro
    • A. Das, R.N. Frank, M.L. Weber, and et al. ATP causes retinal pericytes to contract in vitro Exp Eye Res 46 1988 349 362
    • (1988) Exp Eye Res , vol.46 , pp. 349-362
    • Das, A.1    Frank, R.N.2    Weber, M.L.3
  • 47
    • 84917332024 scopus 로고    scopus 로고
    • Etiologic mechanisms in diabetic retinopathy
    • S.J. Ryan, Elsevier Mosby Philadelphia, PA
    • R.N. Frank Etiologic mechanisms in diabetic retinopathy S.J. Ryan, Retina Volume II 2006 Elsevier Mosby Philadelphia, PA 1241 1270
    • (2006) RetinaVolume II , pp. 1241-1270
    • Frank, R.N.1
  • 48
    • 0030756325 scopus 로고    scopus 로고
    • Pericyte loss and microaneurysm formation in PDGF-B deficient mice
    • P. Lindahl, B.R. Johansson, P. Levéen, and et al. Pericyte loss and microaneurysm formation in PDGF-B deficient mice Science 277 1997 242 245
    • (1997) Science , vol.277 , pp. 242-245
    • Lindahl, P.1    Johansson, B.R.2    Levéen, P.3
  • 49
    • 0023585264 scopus 로고
    • Inhibition of capillary cell growth by pericytes and smooth muscle cells
    • A. Orlidge, and P.A. D'Amore Inhibition of capillary cell growth by pericytes and smooth muscle cells J Cell Biol 105 1987 1455 1462
    • (1987) J Cell Biol , vol.105 , pp. 1455-1462
    • Orlidge, A.1    D'Amore, P.A.2
  • 50
    • 0025055497 scopus 로고
    • Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening - prevention by an aldose reductase inhibitor
    • A. Das, R.N. Frank, N.L. Zhang, and et al. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening - prevention by an aldose reductase inhibitor Exp Eye Res 50 1990 269 280
    • (1990) Exp Eye Res , vol.50 , pp. 269-280
    • Das, A.1    Frank, R.N.2    Zhang, N.L.3
  • 52
    • 74849117723 scopus 로고    scopus 로고
    • The neurovascular unit in the setting of stroke
    • G.J. Del Zoppo The neurovascular unit in the setting of stroke J Intern Med 267 2010 156 171
    • (2010) J Intern Med , vol.267 , pp. 156-171
    • Del Zoppo, G.J.1
  • 53
    • 0031594369 scopus 로고    scopus 로고
    • Muller cell changes in human diabetic retinopathy
    • M. Mizutani, C. Gerhardinger, and M. Lorenzi Muller cell changes in human diabetic retinopathy Diabetes 47 1998 445 449
    • (1998) Diabetes , vol.47 , pp. 445-449
    • Mizutani, M.1    Gerhardinger, C.2    Lorenzi, M.3
  • 54
    • 84860221553 scopus 로고    scopus 로고
    • Inner retinal visual dysfunction is a sensitive marker of nonproliferative diabetic retinopathy
    • G.R. Jackson, I.U. Scott, D.A. Quillen, and et al. Inner retinal visual dysfunction is a sensitive marker of nonproliferative diabetic retinopathy Br J Ophthalmol 96 2012 699 703
    • (2012) Br J Ophthalmol , vol.96 , pp. 699-703
    • Jackson, G.R.1    Scott, I.U.2    Quillen, D.A.3
  • 55
    • 0037376768 scopus 로고    scopus 로고
    • A new view of diabetic retinopathy: a neurodegenerative disease of the eye
    • A.J. Barber A new view of diabetic retinopathy: a neurodegenerative disease of the eye Prog Neuropsychopharmacol Biol Psychiatry 27 2003 283 290
    • (2003) Prog Neuropsychopharmacol Biol Psychiatry , vol.27 , pp. 283-290
    • Barber, A.J.1
  • 56
    • 34248215127 scopus 로고    scopus 로고
    • Retinopathy is decreased during experimental diabetes in a mouse model of outer retinal degeneration
    • T.E. de Gooyer, K.A. Stevenson, P. Humphries, and et al. Retinopathy is decreased during experimental diabetes in a mouse model of outer retinal degeneration Invest Ophthalmol Vis Sci 47 2006 5561 5568
    • (2006) Invest Ophthalmol Vis Sci , vol.47 , pp. 5561-5568
    • De Gooyer, T.E.1    Stevenson, K.A.2    Humphries, P.3
  • 57
    • 0035086992 scopus 로고    scopus 로고
    • The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment
    • G.B. Arden The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment Br J Ophthalmol 85 2001 366 370
    • (2001) Br J Ophthalmol , vol.85 , pp. 366-370
    • Arden, G.B.1
  • 58
    • 84885357617 scopus 로고    scopus 로고
    • Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina
    • Y. Du, A. Veenstra, K. Palczewski, and T.S. Kern Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina Proc Natl Acad Sci U S A 110 2013 16586 16591
    • (2013) Proc Natl Acad Sci U S A , vol.110 , pp. 16586-16591
    • Du, Y.1    Veenstra, A.2    Palczewski, K.3    Kern, T.S.4
  • 59
    • 0024551654 scopus 로고
    • Immunolocalization of blood-retinal barrier breakdown in human diabetics
    • S. Vinores, C. Gadegbaku, P.A. Campochiaro, and et al. Immunolocalization of blood-retinal barrier breakdown in human diabetics Am J Pathol 134 1989 231 235
    • (1989) Am J Pathol , vol.134 , pp. 231-235
    • Vinores, S.1    Gadegbaku, C.2    Campochiaro, P.A.3
  • 60
    • 79955995693 scopus 로고    scopus 로고
    • Significance of outer blood-retina barrier breakdown in diabetes and ischemia
    • H.Z. Xu, and Y.Z. Le Significance of outer blood-retina barrier breakdown in diabetes and ischemia Invest Ophthalmol Vis Sci 52 2011 2160 2164
    • (2011) Invest Ophthalmol Vis Sci , vol.52 , pp. 2160-2164
    • Xu, H.Z.1    Le, Y.Z.2
  • 61
    • 42449135678 scopus 로고    scopus 로고
    • Immunological mechanisms in the pathogenesis of diabetic retinopathy
    • A.P. Adamis, and A.J. Berman Immunological mechanisms in the pathogenesis of diabetic retinopathy Semin Immunopathol 30 2008 65 84
    • (2008) Semin Immunopathol , vol.30 , pp. 65-84
    • Adamis, A.P.1    Berman, A.J.2
  • 62
    • 0032863021 scopus 로고    scopus 로고
    • Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition
    • K. Miyamoto, S. Khosrof, S.E. Bursell, and et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition Proc Natl Acad Sci U S A 96 1999 10836 10841
    • (1999) Proc Natl Acad Sci U S A , vol.96 , pp. 10836-10841
    • Miyamoto, K.1    Khosrof, S.2    Bursell, S.E.3
  • 63
    • 7044228789 scopus 로고    scopus 로고
    • A central role of inflammation in the pathogenesis of diabetic retinopathy
    • A.M. Joussen, V. Poulaki, M.L. Le, and et al. A central role of inflammation in the pathogenesis of diabetic retinopathy FASEB J 18 2004 1450 1452
    • (2004) FASEB J , vol.18 , pp. 1450-1452
    • Joussen, A.M.1    Poulaki, V.2    Le, M.L.3
  • 64
    • 0029162588 scopus 로고
    • Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid
    • D.S. McLeod, D.J. Lefer, C. Merges, and G.A. Lutty Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid Am J Pathol 147 1995 642 653
    • (1995) Am J Pathol , vol.147 , pp. 642-653
    • McLeod, D.S.1    Lefer, D.J.2    Merges, C.3    Lutty, G.A.4
  • 65
    • 17844381920 scopus 로고    scopus 로고
    • Neutrophils are associated with capillary closure in spontaneously diabetic monkey retinas
    • S.Y. Kim, S.Y. Kim, M.A. Johnson, and et al. Neutrophils are associated with capillary closure in spontaneously diabetic monkey retinas Diabetes 54 2005 1534 1542
    • (2005) Diabetes , vol.54 , pp. 1534-1542
    • Kim, S.Y.1    Kim, S.Y.2    Johnson, M.A.3
  • 66
    • 84908200342 scopus 로고    scopus 로고
    • Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier diabetic retinopathy
    • S. Rangasamy, P.G. McGuire, C. Franco Nitta, and et al. Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier diabetic retinopathy PLoS One 9 2014 e108508
    • (2014) PLoS One , vol.9
    • Rangasamy, S.1    McGuire, P.G.2    Franco Nitta, C.3
  • 67
    • 57949110908 scopus 로고    scopus 로고
    • Association of vitreous inflammatory markers in diabetic macular edema
    • H. Funatsu, H. Noma, T. Mimura, and et al. Association of vitreous inflammatory markers in diabetic macular edema Ophthalmology 116 2009 73 79
    • (2009) Ophthalmology , vol.116 , pp. 73-79
    • Funatsu, H.1    Noma, H.2    Mimura, T.3
  • 68
    • 84964311648 scopus 로고    scopus 로고
    • Systemic therapies for diabetic retinopathy: the ACCORD Eye Study (editorial)
    • R.N. Frank Systemic therapies for diabetic retinopathy: the ACCORD Eye Study (editorial) Ophthalmology 121 2014 2295 2296
    • (2014) Ophthalmology , vol.121 , pp. 2295-2296
    • Frank, R.N.1
  • 69
    • 84961289893 scopus 로고    scopus 로고
    • The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
    • E. Chew, M.D. Davis, R. Danis, and et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study Ophthalmology 121 2014 2443 2451
    • (2014) Ophthalmology , vol.121 , pp. 2443-2451
    • Chew, E.1    Davis, M.D.2    Danis, R.3
  • 70
    • 33745782356 scopus 로고    scopus 로고
    • Diabetic macular edema associated with glitazone use
    • E.H. Ryan Jr., D.P. Han, R.C. Ramsay, and et al. Diabetic macular edema associated with glitazone use Retina 26 2006 562 570
    • (2006) Retina , vol.26 , pp. 562-570
    • Ryan, E.H.1    Han, D.P.2    Ramsay, R.C.3
  • 71
    • 82455180438 scopus 로고    scopus 로고
    • VEGF and PEDF secretions over time following various laser irradiations on an RPE organ culture
    • Y. Miura, F. Treumer, A. Klettner, and et al. VEGF and PEDF secretions over time following various laser irradiations on an RPE organ culture Invest Ophthalmol Vis Sci 51 2010 469
    • (2010) Invest Ophthalmol Vis Sci , vol.51 , pp. 469
    • Miura, Y.1    Treumer, F.2    Klettner, A.3
  • 72
    • 77952779304 scopus 로고    scopus 로고
    • Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema
    • Diabetic Retinopathy Clinical Research Network Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077
    • (2010) Ophthalmology , vol.117 , pp. 1064-1077
  • 73
    • 84868208071 scopus 로고    scopus 로고
    • Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three year randomized trial results
    • Diabetic Retinopathy Clinical Research Network Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three year randomized trial results Ophthalmology 119 2012 2312 2318
    • (2012) Ophthalmology , vol.119 , pp. 2312-2318
  • 74
    • 70349973297 scopus 로고    scopus 로고
    • Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular edema
    • J. Figueira, J. Khan, S. Nunes, and et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular edema Br J Ophthalmol 93 2009 1341 1344
    • (2009) Br J Ophthalmol , vol.93 , pp. 1341-1344
    • Figueira, J.1    Khan, J.2    Nunes, S.3
  • 75
    • 77952891868 scopus 로고    scopus 로고
    • Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction
    • Diabetic Retinopathy Clinical Research Network Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction Ophthalmology 117 2010 1087 1093
    • (2010) Ophthalmology , vol.117 , pp. 1087-1093
  • 77
    • 0036247969 scopus 로고    scopus 로고
    • Potential medical therapies for diabetic retinopathy
    • R.N. Frank Potential medical therapies for diabetic retinopathy Am J Ophthalmol 133 2002 693 698
    • (2002) Am J Ophthalmol , vol.133 , pp. 693-698
    • Frank, R.N.1
  • 78
    • 33947236725 scopus 로고    scopus 로고
    • Effect of ruboxistaurin in patients with diabetic macular edema: thirty month results of the PKC-DMES clinical trial
    • PKC-DMES Study Group Effect of ruboxistaurin in patients with diabetic macular edema: thirty month results of the PKC-DMES clinical trial Arch Ophthalmol 125 2007 318 324
    • (2007) Arch Ophthalmol , vol.125 , pp. 318-324
  • 79
    • 0031126380 scopus 로고    scopus 로고
    • Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates
    • H. Ozaki, H. Hayashi, S.A. Vinores, and et al. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates Exp Eye Res 64 1997 505 517
    • (1997) Exp Eye Res , vol.64 , pp. 505-517
    • Ozaki, H.1    Hayashi, H.2    Vinores, S.A.3
  • 80
    • 0033838925 scopus 로고    scopus 로고
    • Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1)
    • K. Miyamoto, S. Khosrof, S.E. Bursell, and et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1) Am J Pathol 156 2000 1733 1739
    • (2000) Am J Pathol , vol.156 , pp. 1733-1739
    • Miyamoto, K.1    Khosrof, S.2    Bursell, S.E.3
  • 81
    • 79958012399 scopus 로고    scopus 로고
    • A Phase 2/3, multicenter, randomized, double-masked, 2 -year trial of pegaptanib sodium for the treatment of diabetic macular edema
    • M.B. Sultan, D. Zhou, J. Loftus Macugen 1013 Study Group A Phase 2/3, multicenter, randomized, double-masked, 2 -year trial of pegaptanib sodium for the treatment of diabetic macular edema Ophthalmology 118 2011 1107 1118
    • (2011) Ophthalmology , vol.118 , pp. 1107-1118
    • Sultan, M.B.1    Zhou, D.2    Loftus, J.3
  • 82
    • 84885022258 scopus 로고    scopus 로고
    • Long-term outcome of ranibizumab therapy for diabetic macular edema: 36 month results from two Phase III trials: RISE and RIDE
    • D.M. Brown, Q.D. Nguyen, D.M. Marcus RIDE and RISE Research Group Long-term outcome of ranibizumab therapy for diabetic macular edema: 36 month results from two Phase III trials: RISE and RIDE Ophthalmology 120 2013 2013 2022
    • (2013) Ophthalmology , vol.120 , pp. 2013-2022
    • Brown, D.M.1    Nguyen, Q.D.2    Marcus, D.M.3
  • 83
    • 84865593623 scopus 로고    scopus 로고
    • A 2-year prospective, randomized, controlled trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema: 24-month data: Report 3
    • R. Rajendram, S. Fraser-Bell, A. Kaines, and et al. A 2-year prospective, randomized, controlled trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema: 24-month data: Report 3 Arch Ophthalmol 130 2012 972 979
    • (2012) Arch Ophthalmol , vol.130 , pp. 972-979
    • Rajendram, R.1    Fraser-Bell, S.2    Kaines, A.3
  • 84
    • 84908897529 scopus 로고    scopus 로고
    • Intravitreal aflibercept for diabetic macular edema
    • J.F. Korobelnik, D.V. Do, U. Schmidt-Erfurth, and et al. Intravitreal aflibercept for diabetic macular edema Ophthalmology 121 2014 2247 2254
    • (2014) Ophthalmology , vol.121 , pp. 2247-2254
    • Korobelnik, J.F.1    Do, D.V.2    Schmidt-Erfurth, U.3
  • 86
    • 84902151808 scopus 로고    scopus 로고
    • Revolution to a new standard treatment of diabetic macular edema
    • L. Jampol, N.B. Bressler, and A.R. Glassman Revolution to a new standard treatment of diabetic macular edema JAMA 311 2014 2269 2270
    • (2014) JAMA , vol.311 , pp. 2269-2270
    • Jampol, L.1    Bressler, N.B.2    Glassman, A.R.3
  • 87
    • 84856397889 scopus 로고    scopus 로고
    • Diabetic retinopathy and inflammation: novel therapeutic targets
    • S. Rangasamy, P.G. McGuire, and A. Das Diabetic retinopathy and inflammation: novel therapeutic targets Middle East Afr J Ophthalmol 19 2012 52 59
    • (2012) Middle East Afr J Ophthalmol , vol.19 , pp. 52-59
    • Rangasamy, S.1    McGuire, P.G.2    Das, A.3
  • 88
    • 84908118639 scopus 로고    scopus 로고
    • Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema
    • D.S. Boyer, Y.H. Yoon, R. Belfort, and et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema Ophthalmology 121 2014 1904 1914
    • (2014) Ophthalmology , vol.121 , pp. 1904-1914
    • Boyer, D.S.1    Yoon, Y.H.2    Belfort, R.3
  • 89
    • 79953329178 scopus 로고    scopus 로고
    • Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema
    • P. Campochiaro, D.M. Brown, A. Pearson, and et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema Ophthalmology 118 2011 626 635
    • (2011) Ophthalmology , vol.118 , pp. 626-635
    • Campochiaro, P.1    Brown, D.M.2    Pearson, A.3
  • 90
    • 79955023336 scopus 로고    scopus 로고
    • Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts
    • A. Thakur, R. Kadam, and U.B. Kompella Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts Arch Ophthalmol 129 2011 914 920
    • (2011) Arch Ophthalmol , vol.129 , pp. 914-920
    • Thakur, A.1    Kadam, R.2    Kompella, U.B.3
  • 91
    • 0036517850 scopus 로고    scopus 로고
    • Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression
    • A.M. Joussen, V. Poulaki, N. Mitsiades, and et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression FASEB J 16 2002 438 440
    • (2002) FASEB J , vol.16 , pp. 438-440
    • Joussen, A.M.1    Poulaki, V.2    Mitsiades, N.3
  • 92
    • 50549220514 scopus 로고
    • Diabetic retinopathy and rheumatoid arthritis
    • E.D. Powell, and R.A. Field Diabetic retinopathy and rheumatoid arthritis Lancet 4 1964 17 18
    • (1964) Lancet , vol.4 , pp. 17-18
    • Powell, E.D.1    Field, R.A.2
  • 93
    • 0024500488 scopus 로고
    • Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial
    • DAMAD Study Group Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial Diabetes 38 1989 491 498
    • (1989) Diabetes , vol.38 , pp. 491-498
  • 94
    • 0025853982 scopus 로고
    • Effects of aspirin treatment on diabetic retinopathy. ETDRS report no. 8. Early Treatment Diabetic Retinopathy Study research group
    • ETDRS Group Effects of aspirin treatment on diabetic retinopathy. ETDRS report no. 8. Early Treatment Diabetic Retinopathy Study research group Ophthalmology 98 5Suppl 1991 757 765
    • (1991) Ophthalmology , vol.98 , Issue.5 , pp. 757-765
  • 95
    • 33847028707 scopus 로고    scopus 로고
    • Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology
    • T.S. Kern, C.M. Miller, T. Du, and et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology Diabetes 56 2007 373 379
    • (2007) Diabetes , vol.56 , pp. 373-379
    • Kern, T.S.1    Miller, C.M.2    Du, T.3
  • 96
    • 84929043837 scopus 로고    scopus 로고
    • Topical nepafenac in eyes with noncentral diabetic macular edema
    • S.M. Friedman, T.H. Almukhtar, C.W. Baker, and et al. Topical nepafenac in eyes with noncentral diabetic macular edema Retina 35 2015 944 956
    • (2015) Retina , vol.35 , pp. 944-956
    • Friedman, S.M.1    Almukhtar, T.H.2    Baker, C.W.3
  • 99
    • 84875242688 scopus 로고    scopus 로고
    • Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study
    • P.A. Campochiaro, R. Channa, B.B. Berger, and et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study Am J Ophthalmol 155 2013 697 704
    • (2013) Am J Ophthalmol , vol.155 , pp. 697-704
    • Campochiaro, P.A.1    Channa, R.2    Berger, B.B.3
  • 100
    • 84855305671 scopus 로고    scopus 로고
    • A randomized dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema
    • P.U. Dugel, M.S. Blumenkranz, J.A. Haller, and et al. A randomized dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema Ophthalmology 119 2012 124 131
    • (2012) Ophthalmology , vol.119 , pp. 124-131
    • Dugel, P.U.1    Blumenkranz, M.S.2    Haller, J.A.3
  • 101
    • 84937731333 scopus 로고    scopus 로고
    • Ohr Pharmaceutical Announces Successful End of Phase II Meeting With the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD. Accessed November 3, 2014
    • Ohr Pharmaceutical Announces Successful End of Phase II Meeting With the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD. http://www.ohrpharmaceutical.com/media-center/press-releases/detail/304/ohr-pharmaceutical-announces-successful-end-of-phase-ii. Accessed November 3, 2014.
  • 102
    • 45749143528 scopus 로고    scopus 로고
    • Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits
    • L. Scheppke, E. Aguilar, R. Gariano, and et al. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits J Clin Invest 118 2008 2337 2346
    • (2008) J Clin Invest , vol.118 , pp. 2337-2346
    • Scheppke, L.1    Aguilar, E.2    Gariano, R.3
  • 103
    • 41149178633 scopus 로고    scopus 로고
    • Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema
    • J. Doukas, S. Mahesh, N. Umeda, and et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema J Cell Physiol 216 2008 29 37
    • (2008) J Cell Physiol , vol.216 , pp. 29-37
    • Doukas, J.1    Mahesh, S.2    Umeda, N.3
  • 104
    • 84872175978 scopus 로고    scopus 로고
    • Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study)
    • Nguyen QD, Schaschar RA, Nduaka CL et al. Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study) Invest Ophthalmol Vis Sci. 2012;53:7666-74.
    • (2012) Invest Ophthalmol Vis Sci , vol.53 , pp. 7666-7674
    • Nguyen, Q.D.1    Schaschar, R.A.2    Nduaka, C.L.3
  • 105
    • 84937730795 scopus 로고    scopus 로고
    • iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema. Accessed November 3, 2014
    • iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema. http://icotherapeutics.com/newsroom/index.php?&content-id=211. Accessed November 3, 2014.
  • 106
    • 77956980190 scopus 로고    scopus 로고
    • Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, cross-over, 32 week study
    • P.P. Sfikakis, V. Grigoropoulos, I. Emfietzoglou, and et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, cross-over, 32 week study Diabetes Care 33 2010 1523 1528
    • (2010) Diabetes Care , vol.33 , pp. 1523-1528
    • Sfikakis, P.P.1    Grigoropoulos, V.2    Emfietzoglou, I.3
  • 107
    • 79955953053 scopus 로고    scopus 로고
    • A potential role of angiopoietin-2 in the regulation of the blood-retinal barrier in diabetic retinopathy
    • S. Rangasamy, R. Srinivasan, J. Maestas, and et al. A potential role of angiopoietin-2 in the regulation of the blood-retinal barrier in diabetic retinopathy Invest Ophthalmol Vis Sci 52 2011 3784 3791
    • (2011) Invest Ophthalmol Vis Sci , vol.52 , pp. 3784-3791
    • Rangasamy, S.1    Srinivasan, R.2    Maestas, J.3
  • 108
    • 0036095059 scopus 로고    scopus 로고
    • Suppression of diabetic retinopathy with angiopoietin-1
    • A.M. Joussen, V. Poulaki, A. Tsujikawa, and et al. Suppression of diabetic retinopathy with angiopoietin-1 Am J Pathol 160 2002 1683 1693
    • (2002) Am J Pathol , vol.160 , pp. 1683-1693
    • Joussen, A.M.1    Poulaki, V.2    Tsujikawa, A.3
  • 109
    • 84907494958 scopus 로고    scopus 로고
    • Targeting VE-PTP activates Tie-2 and stabilizes the ocular vasculature
    • J. Shen, M. Frye, B.L. Lee, and et al. Targeting VE-PTP activates Tie-2 and stabilizes the ocular vasculature J Clin Invest 124 2014 4564 4576
    • (2014) J Clin Invest , vol.124 , pp. 4564-4576
    • Shen, J.1    Frye, M.2    Lee, B.L.3
  • 110
    • 84937733270 scopus 로고    scopus 로고
    • Aerpio Therapeutics Presents Full Results from Phase 1b/2a Study of AKB-9778 for the Treatment of Diabetic Macular Edema. Accessed November 3, 2014
    • Aerpio Therapeutics Presents Full Results from Phase 1b/2a Study of AKB-9778 for the Treatment of Diabetic Macular Edema. http://aerpio.com/news/Aerpio-ARVO-2014-Data.pdf. Accessed November 3, 2014.
  • 111
    • 84937735539 scopus 로고    scopus 로고
    • A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema. Identifier: NCT01994291. Accessed November 3, 2014.
    • A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema. ClinicalTrials.gov Identifier: NCT01994291. Accessed November 3, 2014.
  • 112
    • 77958137681 scopus 로고    scopus 로고
    • Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR)
    • V.R. Rao, E. Prescott, N.B. Shelke, and et al. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR) Invest Ophthalmol Vis Sci 51 2010 5198 5204
    • (2010) Invest Ophthalmol Vis Sci , vol.51 , pp. 5198-5204
    • Rao, V.R.1    Prescott, E.2    Shelke, N.B.3
  • 114
    • 84555187190 scopus 로고    scopus 로고
    • Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema
    • M. Tanito, K. Hara, Y. Takai, and et al. Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema Invest Ophthalmol Vis Sci 52 2011 7944 7948
    • (2011) Invest Ophthalmol Vis Sci , vol.52 , pp. 7944-7948
    • Tanito, M.1    Hara, K.2    Takai, Y.3
  • 115
    • 84937725806 scopus 로고    scopus 로고
    • Phase II clinical trial to evaluate LE-MPP (KPI-121) in patients with retinal vein occlusion and diabetic macular edema. Available at:. Accessed November 3, 2014
    • Phase II clinical trial to evaluate LE-MPP (KPI-121) in patients with retinal vein occlusion and diabetic macular edema. Available at: http://www.kalarx.com/docs/Kala%20Trial%20July%20Initiation%20PR%20Final%207.31.14.pdf. Accessed November 3, 2014.
  • 116
    • 84937726400 scopus 로고    scopus 로고
    • About Optina for the Oral Treatment of Diabetic Macular Edema Available at:. Accessed November 3, 2014
    • About Optina for the Oral Treatment of Diabetic Macular Edema Available at: http://ampiopharma.com/pipeline/optina/. Accessed November 3, 2014.
  • 118
    • 84866756933 scopus 로고    scopus 로고
    • Oral minocycline for the treatment of diabetic macular edema (DME): results of a Phase I/II clinical study
    • C.A. Cukras, P. Petrou, E.Y. Chew, and et al. Oral minocycline for the treatment of diabetic macular edema (DME): results of a Phase I/II clinical study Invest Ophthalmol Vis Sci 53 2012 3865 3874
    • (2012) Invest Ophthalmol Vis Sci , vol.53 , pp. 3865-3874
    • Cukras, C.A.1    Petrou, P.2    Chew, E.Y.3
  • 119
    • 84876584591 scopus 로고    scopus 로고
    • Plasma kallikrein-kinin system and diabetic retinopathy
    • J. Liu, and E.P. Feener Plasma kallikrein-kinin system and diabetic retinopathy Biol Chem 394 2013 319 328
    • (2013) Biol Chem , vol.394 , pp. 319-328
    • Liu, J.1    Feener, E.P.2
  • 120
    • 84937733454 scopus 로고    scopus 로고
    • KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema. Accessed November 3, 2014.
    • KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema. Available at: http://www.kalvista.com/news/44/152/KalVista-Pharmaceuticals-Announces-Start-of-Clinical-Development-for-Novel-Treatment-for-Diabetic-Macular-Edema.html. Accessed November 3, 2014.
  • 121
    • 34548397756 scopus 로고    scopus 로고
    • Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetic retinopathy
    • D. Navaratna, P.G. McGuire, G. Menicucci, and A. Das Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetic retinopathy Diabetes 56 2007 2380 2387
    • (2007) Diabetes , vol.56 , pp. 2380-2387
    • Navaratna, D.1    McGuire, P.G.2    Menicucci, G.3    Das, A.4
  • 123
    • 84937734640 scopus 로고    scopus 로고
    • Allegro Ophthalmics begins phase 2 clinical trial of Luminate® (Alg-1001) for the treatment of diabetic macular edema. Accessed January 3, 2014
    • Allegro Ophthalmics begins phase 2 clinical trial of Luminate® (Alg-1001) for the treatment of diabetic macular edema. Available at: http://www.allegroeye.com/press/. Accessed January 3, 2014.
  • 124
    • 84878590884 scopus 로고    scopus 로고
    • Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment
    • T. Inoue, M. Morita, T. Tojo, and et al. Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment Bioorg Med Chem 21 2013 3873 3881
    • (2013) Bioorg Med Chem , vol.21 , pp. 3873-3881
    • Inoue, T.1    Morita, M.2    Tojo, T.3
  • 125
    • 79551607371 scopus 로고    scopus 로고
    • Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus
    • J.D. Wu, X.H. Xu, J. Zhu, and et al. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus Diabetes Technol Ther 13 2011 143 148
    • (2011) Diabetes Technol Ther , vol.13 , pp. 143-148
    • Wu, J.D.1    Xu, X.H.2    Zhu, J.3
  • 126
    • 84905401253 scopus 로고    scopus 로고
    • Regression of diabetic macular edema after subcutaneous exenatide
    • V. Sarao, D. Veritti, and P. Lanzetta Regression of diabetic macular edema after subcutaneous exenatide Acta Diabetol 51 2014 505 508
    • (2014) Acta Diabetol , vol.51 , pp. 505-508
    • Sarao, V.1    Veritti, D.2    Lanzetta, P.3
  • 128
    • 77950863290 scopus 로고    scopus 로고
    • Topical mecamylamine for diabetic macular edema
    • P.A. Campochiaro, S.M. Shah, G. Hafiz, and et al. Topical mecamylamine for diabetic macular edema Am J Ophthalmol 149 2010 839 851
    • (2010) Am J Ophthalmol , vol.149 , pp. 839-851
    • Campochiaro, P.A.1    Shah, S.M.2    Hafiz, G.3
  • 129
    • 69249110875 scopus 로고    scopus 로고
    • Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown
    • V. Haurigot, P. Villacampa, A. Ribera, and et al. Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown J Biol Chem 284 2009 22961 22969
    • (2009) J Biol Chem , vol.284 , pp. 22961-22969
    • Haurigot, V.1    Villacampa, P.2    Ribera, A.3
  • 130
    • 84937733767 scopus 로고    scopus 로고
    • A phase 1, open-label safety and pharmacodynamic study of RV 001, an insulin-like growth factor-1 receptor (IGF-1) antagonist, given by IV infusion in patients with center-involved diabetic macular edema (DME). Accessed November, 3, 2014
    • A phase 1, open-label safety and pharmacodynamic study of RV 001, an insulin-like growth factor-1 receptor (IGF-1) antagonist, given by IV infusion in patients with center-involved diabetic macular edema (DME). Available at: http://clinicaltrials.gov/show/NCT02103283. Accessed November, 3, 2014.
  • 131
    • 0029000956 scopus 로고
    • Erythropoietin in diabetic macular edema and renal insufficiency
    • E.A. Friedman, C.D. Brown, and D.H. Berman Erythropoietin in diabetic macular edema and renal insufficiency Am J Kidney Dis 26 1995 202 208
    • (1995) Am J Kidney Dis , vol.26 , pp. 202-208
    • Friedman, E.A.1    Brown, C.D.2    Berman, D.H.3
  • 132
    • 76149132661 scopus 로고    scopus 로고
    • Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema
    • W. Li, S.H. Sinclair, and G.T. Xu Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema Ophthalmic Surg Lasers Imaging 41 2010 18 25
    • (2010) Ophthalmic Surg Lasers Imaging , vol.41 , pp. 18-25
    • Li, W.1    Sinclair, S.H.2    Xu, G.T.3
  • 134
    • 80051600747 scopus 로고    scopus 로고
    • Cell-based therapies for diabetic retinopathy
    • L.C. Shaw, M.B. Neu, and M.B. Grant Cell-based therapies for diabetic retinopathy Curr Diab Rep 11 2011 265 274
    • (2011) Curr Diab Rep , vol.11 , pp. 265-274
    • Shaw, L.C.1    Neu, M.B.2    Grant, M.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.